-
1
Kangfuxin solution significantly reduced probing depth and clinical attachment level in chronic periodontitis patients undergoing implant rehabilitation.
-
2
The incidence of peri-implantitis was only 3.0% in patients treated with Kangfuxin, compared to a historical benchmark of 12%.
-
3
Masticatory function improved, with bite force increasing by 39.6% and the mixing ability index rising significantly after 6 months.
-
4
Inflammatory biomarkers IL-1β, IL-6, and TNF-α decreased significantly, indicating reduced inflammation associated with Kangfuxin treatment.
-
5
The study demonstrated a favorable safety profile for Kangfuxin, with minimal adverse events and a high implant survival rate of 99.6%.
